{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:57:16Z","timestamp":1784923036399,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102607","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T11:45:13Z","timestamp":1752666313000},"page":"102607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Insights into platelet post-transfusional human leukocyte antigen\u00a0I immunization"],"prefix":"10.1016","volume":"96","author":[{"given":"Gabriel","family":"Rojas-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Ma\u00eetre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102607_bib1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000205478","article-title":"[Iso-leuko-antibodies]","volume":"20","author":"Dausset","year":"1958","journal-title":"Acta Haematol"},{"key":"10.1016\/j.coi.2025.102607_bib2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.V58.5.1007.1007","article-title":"Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized","volume":"58","author":"Dutcher","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_bib3","article-title":"Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates","volume":"10","author":"Cao","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2025.102607_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.humimm.2018.06.003","article-title":"Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: a multi-center study","volume":"79","author":"Huo","year":"2018","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib5","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1111\/trf.12727","article-title":"Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy","volume":"54","author":"De Clippel","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib6","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2009.02813.x","article-title":"Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies","volume":"9","author":"Loupy","year":"2009","journal-title":"Am J Transpl J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.coi.2025.102607_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2016030368","article-title":"Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss","volume":"28","author":"Viglietti","year":"2017","journal-title":"J Am Soc Nephrol\u00a0JASN"},{"key":"10.1016\/j.coi.2025.102607_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.humimm.2015.06.013","article-title":"Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation","volume":"76","author":"Higgins","year":"2015","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O'Leary","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2025.102607_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/TP.0000000000005140","article-title":"HLA mismatches identified by a novel algorithm predict risk of antibody-mediated rejection from de novo donor-specific antibodies","volume":"109","author":"Zhang","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2025.102607_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2215\/CJN.13401118","article-title":"Preformed donor-specific HLA antibodies in living and deceased donor transplantation: a multicenter study","volume":"14","author":"Ziemann","year":"2019","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.coi.2025.102607_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/trf.15056","article-title":"The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients","volume":"59","author":"Saris","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib13","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1537-2995.2009.02206.x","article-title":"The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy","volume":"49","author":"Triulzi","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib14","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jhep.2014.06.029","article-title":"Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors","volume":"61","author":"Del Bello","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102607_bib15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/TP.0b013e318186d87b","article-title":"\"Natural\" human leukocyte antigen antibodies found in nonalloimmunized healthy males","volume":"86","author":"Morales-Buenrostro","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.coi.2025.102607_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ajt.12512","article-title":"Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology","volume":"14","author":"Sicard","year":"2014","journal-title":"Am J Transpl\u00a0J Am Soc Transpl Am Soc Transpl Surg"},{"key":"10.1016\/j.coi.2025.102607_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125367","article-title":"Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: from mechanisms and determinants to therapeutic prospects","volume":"14","author":"Couvidou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-62703-493-7_2","article-title":"Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury","volume":"1034","author":"Valenzuela","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.coi.2025.102607_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1179036","article-title":"Prospective assessment of pre-existing and de novo anti-HLA IgE in kidney, liver, lung and heart transplantation","volume":"14","author":"Mucha","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/iji.12363","article-title":"Anti-HLA alloantibodies of the IgA isotype in re-transplant candidates part II: correlation with graft survival","volume":"45","author":"Arnold","year":"2018","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.coi.2025.102607_bib21","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102607_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0887-7963(98)80002-3","article-title":"Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions","volume":"12","author":"Vamvakas","year":"1998","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.coi.2025.102607_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/trf.16201","article-title":"HLA molecule expression on the surface of cells and microparticles in platelet concentrates","volume":"61","author":"Pannetier","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V68.3.627.627","article-title":"Quantitative analysis of platelet surface HLA by W6\/32 anti-HLA monoclonal antibody","volume":"68","author":"Kao","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1537-2995.2002.00051.x","article-title":"Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens","volume":"42","author":"Saito","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41409-019-0482-8","article-title":"Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor","volume":"54","author":"Yamashita","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.coi.2025.102607_bib27","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.4049\/jimmunol.1800683","article-title":"Predicting humoral alloimmunity from differences in donor and recipient HLA surface electrostatic potential","volume":"201","author":"Mallon","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib28","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.16116","article-title":"Dominant immune response to HLA-B57\/B58 molecules after platelet transfusion","volume":"60","author":"Coombs","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_sbref29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136417","article-title":"Comprehensive analysis of the naturally processed peptide repertoire: differences between HLA-A and B in the immunopeptidome","volume":"10","author":"Schellens","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102607_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2017-07-799270","article-title":"Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization","volume":"131","author":"Saris","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_sbref31","first-page":"440","article-title":"HLA class I expression on human platelets is highly variable and correlates with distinct allele group frequencies","volume":"22","author":"Cantisani","year":"2024","journal-title":"Blood Transfus"},{"key":"10.1016\/j.coi.2025.102607_bib32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJM199110243251704","article-title":"Pretransplantation blood transfusion revisited","volume":"325","author":"van Twuyver","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102607_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2014.07.005","article-title":"The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates","volume":"28","author":"Kaiser-Guignard","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.coi.2025.102607_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2018-02-831289","article-title":"Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial","volume":"132","author":"van der Meer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_sbref35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/trf.17200","article-title":"Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: the BEST collaborative study","volume":"63","author":"Cognasse","year":"2023","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib36","first-page":"409","article-title":"Lipidomic analysis of differently prepared platelet concentrates in additive solution during storage","volume":"21","author":"Duchez","year":"2023","journal-title":"Blood Transfus"},{"key":"10.1016\/j.coi.2025.102607_bib37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/trf.13373","article-title":"Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers","volume":"56","author":"Cognasse","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01251","article-title":"Storage-induced platelet apoptosis is a potential risk factor for alloimmunization upon platelet transfusion","volume":"9","author":"Saris","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tmrv.2020.09.010","article-title":"Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness","volume":"34","author":"Saris","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.coi.2025.102607_bib40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.exphem.2016.07.004","article-title":"The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia","volume":"44","author":"Aslam","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.coi.2025.102607_bib41","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/j.1537-2995.2011.03550.x","article-title":"CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice","volume":"52","author":"Gilson","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood.V95.5.1735.005k47_1735_1742","article-title":"Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens","volume":"95","author":"Bang","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_bib43","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2022008411","article-title":"Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice","volume":"7","author":"Couvidou","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2025.102607_sbref44","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2024.04.008","article-title":"Platelets: orchestrators of immunity in host defense and beyond","volume":"57","author":"Nicolai","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102607_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41581-024-00927-w","article-title":"Trained immunity: from kidney failure to organ transplantation","volume":"21","author":"Ochando","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.coi.2025.102607_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41590-020-00845-6","article-title":"Trained immunity, tolerance, priming and differentiation: distinct immunological processes","volume":"22","author":"Divangahi","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1302\/2046-3758.112.BJR-2021-0279.R1","article-title":"Platelets mediate trained immunity against bone and joint infections in a mouse model","volume":"11","author":"Gao","year":"2022","journal-title":"Bone Jt Res"},{"key":"10.1016\/j.coi.2025.102607_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V57.3.395.bloodjournal573395","article-title":"Alloimmunization following platelet transfusion: the absence of a dose-response relationship","volume":"57","author":"Dutcher","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102607_bib49","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1537-2995.2003.00390.x","article-title":"HLA and RBC immunization after filtered and buffy coat-depleted blood transfusion in cardiac surgery: a randomized controlled trial","volume":"43","author":"van de Watering","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.coi.2025.102607_sbref50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165973","article-title":"Divergent CD4(+) T-cell profiles are associated with anti-HLA alloimmunization status in platelet-transfused AML patients","volume":"14","author":"Khelfa","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102607_sbref51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1281123","article-title":"Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice","volume":"14","author":"Jackman","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102607_bib52","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","author":"von Pawel-Rammingen","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2025.102607_bib53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16385","article-title":"A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients","volume":"189","author":"Vo","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:21:25Z","timestamp":1757337685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"alternative-id":["S0952791525000834"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102607","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into platelet post-transfusional human leukocyte antigen\u00a0I immunization","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102607","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102607"}}